Acarizax for treating allergic rhinitis or allergic rhinoconjunctivitis in children aged 5 to 11 years old


featured image

Acarizax is in development for the treatment of house dust mite (HDM) allergic rhinitis or rhinoconjunctivitis in children aged 5 to 11 years old with or without asthma. HDM allergic rhinitis is caused by an allergic reaction to HDM and leads to symptoms similar to a cold, including sneezing, a runny or blocked nose and a cough.

Interventions: Acarizax
Therapeutic Areas: Immunology , Ophthalmology
Year: 2024

Acarizax is in development for the treatment of house dust mite (HDM) allergic rhinitis or rhinoconjunctivitis in children aged 5 to 11 years old with or without asthma. HDM allergic rhinitis is caused by an allergic reaction to HDM and leads to symptoms similar to a cold, including sneezing, a runny or blocked nose and a cough. Allergic rhinitis is often associated with the eye condition conjunctivitis. Allergic rhinoconjunctivitis is an allergic disorder of the nose and eyes. Symptoms include itching, sneezing, watery nasal discharge, nasal congestion and watery, red and/or itchy eyes. Of the three primary treatments used to manage allergic rhinitis – allergen avoidance, pharmacotherapy, and allergen immunotherapy – immunotherapy is the only treatment that that has a disease-modifying effect.